ArticleEuropean journal of medical research2025
Global Burden of Disease of interstitial lung disease and pulmonary sarcoidosis in adolescents and young adults (1990-2019), and projections for the next 30 years.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterstitial lung disease (ILD) and pulmonary sarcoidosis are common respiratory diseases that are difficult to diagnose and costly to treat. Adolescents and young adults (AYAs) aged 15-39 years are frequently overlooked in global burden estimates despite their unique epidemiological and societal implications. Comprehensive global burden estimates are lacking. To address this gap, we analysed the results of the Global Burden of Disease Study (GBD) 2019, focusing on Disability-Adjusted Life Years (DALYs).
methodsUsing the GBD 2019 dataset, we calculated age-standardised rate of incidence, mortality, and DALYs and their average annual percentage change from 1990 to 2019 across various factors, including sex, socio-demographic index (SDI), and geographic region. Decomposition analyses explored the impacts of population growth, changing age structures, and epidemiological changes on ILD incidence, DALYs, and mortality in AYAs globally and across different SDI and GBD regions.interstitial lung disease and pulmonary sarcoidosis among adolescents and young adults trends from 2020 to 2049 were predicted using Bayesian Age-Period-Cohort (BAPC).
resultsIn 2019, there were 2.6 million cases of ILD and pulmonary sarcoidosis in AYAs, and 3,428 deaths were attributed to these diseases. Age-standardised incidence and DALY rates significantly increased between 1990 and 2019. Females experienced higher rates than males. Standardised DALY rates decreased in high and middle-high SDI countries but increased in low, middle-low, and low-SDI countries. The primary reason was population growth, significantly impacting areas in the lower SDI quintiles.The BAPC model projected a gradual increase in the interstitial lung disease and pulmonary sarcoidosis in adolescents and young adults burden from 2020 to 2049.
conclusionsThis study provides recent epidemiological data on the burden of ILD and pulmonary sarcoidosis in AYAs. These findings highlight the importance of targeted control measures to reduce the burden in this age group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.